Opthea (NASDAQ:OPT) Given New $12.00 Price Target at HC Wainwright

Opthea (NASDAQ:OPT) had its price target decreased by HC Wainwright from $14.00 to $12.00 in a report published on Tuesday morning, Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Opthea Price Performance

Shares of OPT opened at $2.91 on Tuesday. The business’s 50-day moving average price is $2.31 and its 200 day moving average price is $2.93. Opthea has a 1-year low of $1.60 and a 1-year high of $4.40.

About Opthea

Opthea Limited, a clinical stage biopharmaceutical company, engages in the development and commercialization of therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage.